Summary
Quest Diagnostics Incorporated (DGX) announced on March 12, 2019, the issuance of $500,000,000 aggregate principal amount of 4.200% Senior Notes due 2029. This debt offering was conducted under the company's existing shelf registration statement and is intended to provide additional capital for general corporate purposes. The notes are senior unsecured obligations and rank equally with other senior unsecured debt, with interest payments due semi-annually and maturity in 2029. The issuance of these notes is a standard financing activity for a company of Quest Diagnostics' size, aimed at managing its capital structure and potentially funding growth initiatives or refinancing existing debt. Investors should note the covenants within the indenture that may restrict certain future actions, such as significant asset sales or additional debt incurrence. The inclusion of a change of control provision offers some protection to noteholders in the event of a significant corporate change.
Key Highlights
- 1Quest Diagnostics issued $500 million in 4.200% Senior Notes due 2029.
- 2The notes were issued on March 12, 2019, under the company's shelf registration statement.
- 3The debt matures on June 30, 2029, with semi-annual interest payments beginning June 30, 2019.
- 4The notes are senior unsecured obligations, ranking equally with other senior unsecured debt.
- 5The Indenture includes covenants that may limit the company's ability to incur certain liens, enter sale/leaseback transactions, merge, or make restricted payments.
- 6A 'change of control' provision requires the company to offer to repurchase the notes at 101% of principal plus accrued interest if triggered.
- 7The filing references an underwriting agreement with major financial institutions, indicating a public offering.